[
  {
    "ts": null,
    "headline": "BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug",
    "summary": "BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.",
    "url": "https://finnhub.io/api/news?id=b2e3405548c48975de7f722f6e0d18102fe3303adf60d79fca2dcdc5c0b56043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732569372,
      "headline": "BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug",
      "id": 131627592,
      "image": "https://media.zenfs.com/en/ibd.com/703850409d67abc5aa561ec3cc7d1f01",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.",
      "url": "https://finnhub.io/api/news?id=b2e3405548c48975de7f722f6e0d18102fe3303adf60d79fca2dcdc5c0b56043"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=55098cd2c901aa6e8db76ed4593cb2219060db8400124c1de80d9919c3e27ee2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732553160,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 131642255,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=55098cd2c901aa6e8db76ed4593cb2219060db8400124c1de80d9919c3e27ee2"
    }
  },
  {
    "ts": null,
    "headline": "Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation",
    "summary": "Intellia Therapeutics (NTLA) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.",
    "url": "https://finnhub.io/api/news?id=2091703562b98aff7fe669e9966ea2c72f145771cf55c53f72db441aa319ff9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732550534,
      "headline": "Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation",
      "id": 131627593,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Intellia Therapeutics (NTLA) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.",
      "url": "https://finnhub.io/api/news?id=2091703562b98aff7fe669e9966ea2c72f145771cf55c53f72db441aa319ff9c"
    }
  },
  {
    "ts": null,
    "headline": "Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?",
    "summary": "Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.",
    "url": "https://finnhub.io/api/news?id=c236d465985c14ee2c3c3a1163a5ff143cc107f87d4a62bf3d42e3fd50fb6d19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732541640,
      "headline": "Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?",
      "id": 131648460,
      "image": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.",
      "url": "https://finnhub.io/api/news?id=c236d465985c14ee2c3c3a1163a5ff143cc107f87d4a62bf3d42e3fd50fb6d19"
    }
  }
]